Cell and Gene Therapy Manufacturing Market Size, Market Forecast and Outlook By FMI
Summary of the Cell and Gene Therapy Manufacturing Market
- Demand and Growth Drivers
- Shifting consumer preferences toward health-conscious and sustainable alternatives are likely to support demand for cell and gene therapy manufacturing products as retail and food service channels expand product assortments.
- Clean-label and plant-based trends are expected to sustain demand growth across developed and emerging markets during the forecast period.
- Distribution channel diversification, including online retail and specialty stores, is likely to expand consumer access and drive volume growth.
- Product and Segment View
- Gene Therapy Manufacturing is likely to remain a leading therapy type segment with 63.9% share, supported by demand from mainstream consumer categories.
- Commercial Scale Manufacturing is likely to lead the scale segment with 67.5% share, reflecting consumer preference for accessibility and convenience.
- Emerging product categories and niche applications are expected to gain share incrementally as formulation technology and distribution access improve.
- Geography and Competitive Outlook
- USA is likely to remain a key market owing to high consumer spending and early adoption of new product formats.
- South Korea is likely to sustain demand on account of growing retail penetration and evolving consumer preferences.
- Companies that can combine product innovation with scalable distribution are likely to gain traction during the forecast period.
- Analyst Opinion
- The Cell and Gene Therapy Manufacturing market is evolving from a niche product space into a mainstream consumer category with clear commercial trajectories.
- Adoption is being shaped by consumer health awareness and willingness to pay for quality differentiation.
- The market is also benefiting from expanding product variety and improved ingredient sourcing.
- Demand is further supported by the need for products that balance taste, nutrition, sustainability, and accessibility across both retail and food service channels.
Cell and Gene Therapy Manufacturing Market Definition
The cell and gene therapy manufacturing market encompasses consumer products, ingredients, and formulations that address the core requirements of therapy type applications across scale, and related end-use categories. The market covers products segmented by therapy type, scale, mode, workflow, spanning the forecast period from 2026 to 2036.
Cell and Gene Therapy Manufacturing Market Inclusions
Market scope encompasses all commercially relevant cell and gene therapy manufacturing products categorized by Therapy Type, Scale, Mode, Workflow. The revenue scope covers the period from 2026 to 2036 across North America, Latin America, Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Cell and Gene Therapy Manufacturing Market Exclusions
The scope does not include unprocessed raw ingredients sold in bulk commodity channels, non-branded products without commercial distribution, or products marketed under categories outside the defined scope.
Cell and Gene Therapy Manufacturing Market Research Methodology
- Primary Research: Product creators, retail customers, and distribution partners in important markets were interviewed by FMI analysts.
- Desk Research: Integrated information from manufacturer reports, trade journals, and trade groups.
- Market sizing and forecasting: Using regional adoption curves and bottom-up aggregation across therapy kind, scale, mode, and workflow categories.
- Data validation: Quarterly cross-checked with manufacturer disclosures and retail tracking data.
Why is the Cell and Gene Therapy Manufacturing Market Growing?
- Changes in what people want in food service and retail channels are creating structured demand for products that are good for the environment, plant-based, and good for your health.
- The USA has the highest growth rate (30.4%) because people spend a lot of money and are quick to adopt new product formats.
- Product innovation in formulation, packaging, and delivery is helping the addressable market grow beyond traditional consumer groups.
The market for making cell and gene therapies is steadily growing because of structural demand factors that are not likely to change during the forecast period. Consumer awareness of where ingredients come from, how healthy they are, and how they affect the environment still affects buying decisions in both high-end and regular stores.
Gene therapy manufacturing has the biggest share of the therapy type segment, with 63.9%. This shows what customers want and how well the product format can be used in different situations and with different preparation methods.
The growth of online shopping and the digitalization of stores are two structural growth reasons. As more people in developed countries use the internet and distribution systems get better in developing markets, the number of people who can buy these things grows.
Market Segmentation Analysis
- The cell and gene therapy manufacturing market is segmented across 4 primary dimensions: Therapy Type, Scale, Mode, Workflow.
- Gene Therapy Manufacturing holds 63.9% of the therapy type segment, reflecting its position as the primary consumer category.
- Commercial Scale Manufacturing leads the scale segment with 67.5% share, reflecting consumer channel preferences.
The market for cell and gene therapy manufacturing is organized across product, end-use, and channel dimensions. Segmentation by therapy type includes Gene Therapy Manufacturing, Cell Therapy Manufacturing, Stem Cell Therapy, Non-Stem Cell Therapy. By scale, the market includes Commercial Scale Manufacturing, Pre-commercial/ R&D Manufacturing.
Insights into the Gene Therapy Manufacturing Therapy Type Segment
In 2026, Gene Therapy Manufacturing is expected to account for 63.9% of the therapy type segment. This product format benefits from consumer familiarity, versatile application properties, and strong positioning across both retail and food service distribution channels.
Consumer preferences continue to evolve, and newer formulation approaches are expected to improve taste, texture, and nutritional profiles within this segment. The expansion of retail availability in emerging markets is likely to sustain volume growth.
Insights into the Commercial Scale Manufacturing Scale Segment
Commercial Scale Manufacturing accounts for 67.5% of the scale segment. This channel benefits from broad consumer traffic, competitive pricing dynamics, and the ability to offer product variety that supports trial and repeat purchase behavior.
Cell and Gene Therapy Manufacturing Market Drivers, Restraints, and Opportunities
- Because people care about their health and the environment, there is a high demand for products that are clearly different from traditional ones.
- The price premium compared to traditional alternatives makes it hard for price-sensitive consumers to adopt, which means that growth is mostly happening in premium and health-conscious retail channels.
- During the projection period, adoption is expected to rise as retail distribution and product awareness grow in emerging markets.
The cell and gene therapy manufacturing market is shaped by a balance of factors that affect demand and factors that limit supply. Consumer preferences are still changing for the better, but the costs of ingredients and problems with distribution slow down the rate of adoption in some price-sensitive groups.
Consumer Health Awareness and Product Innovation
Demand reflects the ongoing shift in consumer purchasing criteria toward health, sustainability, and ingredient transparency. As product awareness grows, the addressable market for differentiated products expands.
Price Premium and Distribution Gaps
Adoption is moderated by the price gap between premium products and conventional alternatives. Consumer willingness to pay varies significantly by geography, income level, and product awareness.
Emerging Market Retail Expansion
Growth reflects increasing retail infrastructure development across Asia, Latin America, and the Middle East. As modern trade penetration and e-commerce access improve, consumer adoption in these regions is expected to accelerate.
Analysis of Cell and Gene Therapy Manufacturing Market By Key Countries
.webp "Top Country Growth Comparison Cell And Gene Therapy Manufacturing Market Cagr (2026 2036)")
| Country |
CAGR |
| USA |
30.4% |
| UK |
16.7% |
| EU |
17.2% |
| Japan |
17.8% |
| South Korea |
18.4% |
- USA is in first place with a 30.4% CAGR, reflecting high consumer spending and early product adoption.
- South Korea at 18.4% shows strong demand because of evolving consumer preferences and retail expansion.
- Japan (17.8%) and EU (17.2%) sustain growth through product innovation and distribution development.
- UK at 16.7% shows that consumer market development is creating new demand opportunities.
The global cell and gene therapy manufacturing market is expected to grow at a rate of 23.8% per year from 2026 to 2036. The study covers more than 30 countries, and the main markets are listed below.
Demand Outlook for Cell and Gene Therapy Manufacturing Market in USA
The USA will grow by 30.4% through 2036. This is supported by consumer spending trends, retail infrastructure development, and increasing product awareness.
- Consumer preference evolution supports demand through retail and food service channels.
- Product variety expansion accelerates consumer trial and repeat purchase.
- Brand investment supports development of next-generation product formats.
Future Outlook for Cell and Gene Therapy Manufacturing Market in the United Kingdom
The UK will grow by 16.7% through 2036. This is supported by consumer spending trends, retail infrastructure development, and increasing product awareness.
- Consumer preference evolution supports demand through retail and food service channels.
- Product variety expansion accelerates consumer trial and repeat purchase.
- Brand investment supports development of next-generation product formats.
Opportunity Analysis of Cell and Gene Therapy Manufacturing Market in the European Union
The European Union will grow by 17.2% through 2036. This is supported by consumer spending trends, retail infrastructure development, and increasing product awareness.
- Consumer preference evolution supports demand through retail and food service channels.
- Product variety expansion accelerates consumer trial and repeat purchase.
- Brand investment supports development of next-generation product formats.
In-depth Analysis of Cell and Gene Therapy Manufacturing Market in Japan
Japan will grow by 17.8% through 2036. This is supported by consumer spending trends, retail infrastructure development, and increasing product awareness.
- Consumer preference evolution supports demand through retail and food service channels.
- Product variety expansion accelerates consumer trial and repeat purchase.
- Brand investment supports development of next-generation product formats.
Sales Analysis of Cell and Gene Therapy Manufacturing Market in South Korea
South Korea will grow by 18.4% through 2036. This is supported by consumer spending trends, retail infrastructure development, and increasing product awareness.
- Consumer preference evolution supports demand through retail and food service channels.
- Product variety expansion accelerates consumer trial and repeat purchase.
- Brand investment supports development of next-generation product formats.
Competitive Landscape and Strategic Positioning
- Lonza Group is the leader in the market with approximately 16.2% share, supported by strong brand recognition, broad distribution, and product innovation capabilities.
- Thermo Fisher Scientific, Catalent Inc., and WuXi Advanced Therapies offer competitive product ranges that address diverse consumer preferences and retail channel requirements.
- New entrants are focusing on specialized applications and niche market segments where premium positioning and ingredient differentiation create competitive advantage.
Lonza Group leads the market through brand equity, distribution scale, and product development capabilities. The competitive landscape is fragmented, with established players competing on product quality, brand positioning, and distribution reach.
Barriers to entry include brand development costs, distribution access requirements, and formulation development complexity. Strategic priorities include product innovation, distribution expansion, and sustainability improvement.
Key Companies in the Cell and Gene Therapy Manufacturing Market
Key global companies leading the cell and gene therapy manufacturing market include:
- Lonza Group, Thermo Fisher Scientific, Catalent Inc., WuXi Advanced Therapies all have strong brand portfolios, distribution networks, and product development capabilities across key markets.
- Fujifilm Diosynth Biotechnologies, Samsung Biologics, BlueRock Therapeutics (Bayer) have established regional strength through targeted product positioning and local distribution partnerships.
- Miltenyi Biotec, Minaris Regenerative Medicine, Vigene Biosciences are emerging players that have gained recognition through product innovation and targeted market positioning.
Competitive Benchmarking: Cell and Gene Therapy Manufacturing Market
| Company |
Product Range |
Brand Strength |
Distribution Access |
Geographic Footprint |
| Lonza Group |
High |
Strong |
Strong |
Global |
| Thermo Fisher Scientific |
High |
Strong |
Strong |
Global |
| Catalent Inc. |
High |
Strong |
Strong |
Global |
| WuXi Advanced Therapies |
Medium |
Medium |
Moderate |
Regional |
| Fujifilm Diosynth Biotechnologies |
Medium |
Medium |
Moderate |
Regional |
| Samsung Biologics |
Medium |
Medium |
Moderate |
Regional |
| BlueRock Therapeutics (Bayer) |
Medium |
Medium |
Low |
Emerging |
| Miltenyi Biotec |
Medium |
Medium |
Low |
Emerging |
| Minaris Regenerative Medicine |
Medium |
Medium |
Low |
Emerging |
| Vigene Biosciences |
Medium |
Medium |
Low |
Emerging |
Source: Future Market Insights competitive analysis, 2026.
Key Developments in Cell and Gene Therapy Manufacturing Market
- In 2025, Lonza Group expanded its cell and gene therapy manufacturing capabilities through the introduction of advanced electroporation technologies and supporting reagents, strengthening its offering for scalable T-cell and gene editing applications.
- In 2025, cell and gene therapy manufacturing continued to see investments in capacity expansion and process innovation by leading CDMOs, with emphasis on viral vector production, automated manufacturing platforms, and scalable solutions for both autologous and allogeneic therapies.
Key Players in the Cell and Gene Therapy Manufacturing Market
Major Global Players
- Lonza Group
- Thermo Fisher Scientific
- Catalent Inc.
- WuXi Advanced Therapies
- Fujifilm Diosynth Biotechnologies
- Samsung Biologics
- BlueRock Therapeutics (Bayer)
Emerging Players/Startups
- Miltenyi Biotec
- Minaris Regenerative Medicine
- Vigene Biosciences
Report Scope and Coverage
| Quantitative Units |
USD 39.76 billion to USD 336.25 billion, at a CAGR of 23.8% |
| Market Definition |
The cell and gene therapy manufacturing market encompasses consumer products and ingredients across therapy type, scale, mode, workflow categories. |
| Regions Covered |
North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered |
USA, UK, EU, Japan, South Korea, 30 plus countries |
| Key Companies Profiled |
Lonza Group, Thermo Fisher Scientific, Catalent Inc., WuXi Advanced Therapies, Fujifilm Diosynth Biotechnologies, Samsung Biologics, BlueRock Therapeutics (Bayer), Miltenyi Biotec, Minaris Regenerative Medicine, Vigene Biosciences |
| Forecast Period |
2026 to 2036 |
| Approach |
Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions. |
Segmentation
Cell and Gene Therapy Manufacturing Market Market Segmented by Therapy Type:
- Gene Therapy Manufacturing
- Cell Therapy Manufacturing
- Stem Cell Therapy
- Non-Stem Cell Therapy
Cell and Gene Therapy Manufacturing Market Market Segmented by Scale:
- Commercial Scale Manufacturing
- Pre-commercial/ R&D Manufacturing
Cell and Gene Therapy Manufacturing Market Market Segmented by Mode:
- Contract Manufacturing
- In-house Manufacturing
Cell and Gene Therapy Manufacturing Market Market Segmented by Workflow:
- Cell Processing
- Cell Banking
- Process Development
- Fill & Finish Operations
- Analytical And Quality Testing
- Raw Material Testing
- Vector Production
- Other Workflows
Cell and Gene Therapy Manufacturing Market Market by Region:
- North America
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
Research Sources and Bibliography
- Food and Agriculture Organization. (2025). FAO Global Food and Beverage Market Report. FAO.
- European Commission. (2025). EU Food Safety and Consumer Health Regulations. EC.
- USA Department of Agriculture. (2025). USDA Economic Research Service Reports. USDA.
- World Health Organization. (2025). WHO Nutrition and Health Guidelines. WHO.
- International Food Information Council. (2025). IFIC Consumer Food Survey. IFIC.
This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.
This Report Answers
- Estimating the size of the market and revenue from 2026 to 2036.
- Segmentation by therapy type, scale, mode, workflow.
- Insights about more than 30 markets in the region.
- Analysis of consumer trends, product innovation, and distribution dynamics.
- Assessment of the competitive landscape.
- Finding investment opportunities across product segments and geographic markets.
- Keeping track of the supply chain.
- Delivery of data in PDF and Excel formats.
Frequently Asked Questions
What is the global market demand for Cell and Gene Therapy Manufacturing in 2026?
In 2026, the global market for cell and gene therapy manufacturing is expected to be worth USD 39.76 billion.
How big will the market for Cell and Gene Therapy Manufacturing be in 2036?
By 2036, the market for cell and gene therapy manufacturing is expected to be worth USD 336.25 billion.
How much do you think demand for Cell and Gene Therapy Manufacturing will grow between 2026 and 2036?
Between 2026 and 2036, the demand for cell and gene therapy manufacturing is expected to grow at a CAGR of 23.8%.
Which Therapy Type segment is likely to be the best seller in the world by 2026?
Gene Therapy Manufacturing is expected to account for 63.9% of the market in 2026, reflecting its strong consumer preference and broad distribution.
What is causing demand to rise in USA?
USA will grow at a rate of 30.4% per year through 2036, supported by high consumer spending and early adoption of new product formats.
What is causing demand to rise in South Korea?
South Korea will grow at a rate of 18.4% per year through 2036, supported by evolving consumer preferences and retail infrastructure development.
What does this report mean by "Cell and Gene Therapy Manufacturing Market definition"?
The cell and gene therapy manufacturing market includes consumer products and ingredients categorized by therapy type, scale, mode, workflow.
How does FMI make the Cell and Gene Therapy Manufacturing forecast and check it?
Forecasting models use a hybrid bottom-up and top-down approach, starting with verified transaction data and checking it against retail tracking data and manufacturer disclosures.
